Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Shots:

• The exploratory analyses of the P-III study evaluate the equivalent efficacy of Aybintio vs reference bevacizumab in combination with paclitaxel & carboplatin, q3w up to 6 cycles followed by Aybintio or reference bevacizumab as maintenance monothx. in 665 patients with metastatic/recurrent nsq. NSCLC
• Results: previous analysis demonstrate ORR in PPS (50.1% vs 44.8%); expanded analysis showed the risk difference in best ORR by 11 & 17wks. (2.2% vs 2.4%); mean of maximum % change from baseline in tumor burden @24wks. (-27.8% vs -27.3%)
• Aybintio is a biosimilar referencing Avastin and has received EC’s approval in Aug’2020 for mCRC, mBC, NSCLC, mRCC, epithelial ovarian, fallopian tube, primary peritoneal cancer and cervical cancer

Click here ­to­ read full press release/ article | Ref: Samsung Bioepis | Image: The Investor